Combined detection of P53, Ki67, P504S, and IMP3: Diagnostic implications for gastric cancer and precursor lesions

Figure 1 Expression of P504S and IMP3 in lesions of atypical hyperplasia, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. A-D: Expression of P504S in atypical hyperplasia (AH), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and adenocarcinoma (AC); E-H: Expression of IMP3 in AH, LGD, HGD, and AC. (IHC × 100).

Figure 2 Differences in P504S and IMP3 expression in gastric mucosal biopsies at different stages. A: Difference in P504S expression in gastric mucosal biopsies at different stages; B: Difference in IMP3 expression in gastric mucosal biopsies at different stages. AH: Atypical hyperplasia; LGD: Low-grade dysplasia; HGD: High-grade dysplasia; AC: Adenocarcinoma.

Figure 3 Correlation between expression of the four proteins in gastric mucosal biopsies. A: Correlation between the expression of IMP3 and P53; B: Correlation between the expression of P504S and P53; C: Correlation between the expression of IMP3 and Ki67; D: Correlation between the expression of P504S and Ki67. ^aP value < 0.05 denotes statistical significance in the comparative analysis.

Figure 4 Receiver operating characteristic curves of the four proteins in predicting gastric mucosal biopsies. A: Receiver operating characteristic (ROC) curves of P504S, Ki67, and their combination in predicting low-grade dysplasia; B: ROC curves of P53, IMP3, and their combination in predicting high-grade dysplasia/adenocarcinoma. ROC: Receiver operating characteristic; AUC: Area under the curve.